Nuvalent’s best-in-class precision oncology pipeline has been transformed into a de-risked merger-arbitrage story capped by GSK’s $124 cash bid.
Overview
Nuvalent is a clinical-stage precision oncology company developing next-generation small-molecule TKIs for genetically defined lung cancers. Its lead assets, zidesamtinib and neladalkib, are designed to overcome resistance mutations, penetrate the CNS, and avoid off-target toxicities that limit legacy therapies. Both have FDA Breakthrough Therapy and Orphan Drug designations, with PDUFA dates in September and November 2026. The investment profile changed materially after GSK agreed to acquire Nuvalent for $124.00 per share in cash, shifting NUVL from a high-risk biotech growth story to a tightly priced merger-arbitrage position.